e-learning
resources
Paris 2018
Tuesday, 18.09.2018
CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effect of genotype on hypersensitivity pneumonitis despite treatment.
M. Šterclová (Prague, Czech Republic), M. PetrEk (Olomouc, Czech Republic), A. Kishore (Olomouc, Czech Republic), J. Skibova (Prague, Czech Republic), M. Vasakova (Prague, Czech Republic)
Source:
International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Session:
CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Session type:
Poster Discussion
Number:
3665
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Šterclová (Prague, Czech Republic), M. PetrEk (Olomouc, Czech Republic), A. Kishore (Olomouc, Czech Republic), J. Skibova (Prague, Czech Republic), M. Vasakova (Prague, Czech Republic). Effect of genotype on hypersensitivity pneumonitis despite treatment.. 3665
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
HISTOLOGICAL FINDINGS IN TRANSBRONCHIAL CRYOBIOPSIES OBTAINED FROM PATIENTS AFTER COVID-19
The impact of anti-IgE treatment on the airway microbiome in asthma.
Does “UIPAF” really exist?
Related content which might interest you:
The effects of oral corticosteroid treatment (OCS) on sequential lung function tests in a cohort of patients with acute hypersensitivity pneumonitis (AHP)
Source: Virtual Congress 2020 – Clinical aspects and new treatment strategies for rare interstitial lung diseases in adults and children
Year: 2020
Consort hypersensitivity pneumonitis
Source: Eur Respir J 2009; 33: 1223-1225
Year: 2009
Diagnosis, course and management of hypersensitivity pneumonitis
Source: Eur Respir Rev, 31 (163) 210169; 10.1183/16000617.0169-2021
Year: 2022
Squeaks in hypersensitivity pneumonitis: prevalence and clinical correlates
Source: International Congress 2019 – Pathogenesis and prognosis of interstitial lung disease of known origin
Year: 2019
Immunomodulatory treatment of severe persistent asthma with interferon-αcon-1 (IFN-αcon-1). Effect on the clinical course of oral corticosteroid dose and eosinophil numbers
Source: Annual Congress 2003 - Modulation of bronchial hyperreactivity and immune response in the airways
Year: 2003
Hypersensitivity pneumonitis associated with the use of temozolomide
Source: Eur Respir J 2009; 33: 931-934
Year: 2009
Hypersensitivity pneumonitis: current concepts
Source: Eur Respir J 2001; 18: 81S-92S
Year: 2001
Treatment of hypersensitivity pneumonitis (HP) - targeting pathways of inflammation and fibrosis
Source: International Congress 2017 – Hypersensitivity pneumonitis: current concepts and perspectives in diagnosis, pathogenesis and management
Year: 2017
Characterisation of patients with chronic hypersensitivity pneumonitis (CHP) - a seven year single centre experience
Source: Virtual Congress 2020 – Clinical issues in granulomatous lung diseases
Year: 2020
Prognostic characteristics in chronic hypersensitivity pneumonitis.
Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020
Age at diagnosis and degree of pulmonary function tests disturbances in hypersensitivity pneumonitis (HP) patients
Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease
Year: 2010
Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: Three case studies.
Source: Virtual Congress 2021 – COVID-19 and management of lung cancer
Year: 2021
Pigeon breeder‘s hypersensitivity pneumonitis – possible antigen exposure reduction after diagnosis in the most susceptible patients
Source: Annual Congress 2009 - High molecular sensitisers and biological dusts
Year: 2009
Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis
Source: ERJ Open Res, 3 (3) 00016-2017; 10.1183/23120541.00016-2017
Year: 2017
Serious infections in sarcoidosis and the effect of treatment
Source: International Congress 2019 – Granulomatous disorders: from bench to bedside
Year: 2019
Importance of unrecognised exposure to avian antigen in chronic bird-related hypersensitivity pneumonitis
Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease
Year: 2009
Effects of treatment with angiotensin-(1-7) on antigen sensitization of murine experimental model of asthma
Source: International Congress 2019 – Modelling and monitoring of airway diseases
Year: 2019
Factors predicting response to azathioprine in chronic hypersensitivity pneumonitis – the importance of BAL lymphocytosis
Source: International Congress 2018 – Clinical aspects of hypersensitivity pneumonitis (HP) and CTD-ILD: diagnosis, monitoring and treatment
Year: 2018
Mechanisms of exercise limitation in patients with chronic hypersensitivity pneumonitis
Source: ERJ Open Res, 4 (3) 00043-2018; 10.1183/23120541.00043-2018
Year: 2018
Impact of BAL lymphocytosis and presence of honeycombing on corticosteroid treatment effect in fibrotic hypersensitivity pneumonitis: a retrospective cohort study
Source: Eur Respir J, 55 (4) 1901983; 10.1183/13993003.01983-2019
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept